{
    "clinical_study": {
        "@rank": "55309", 
        "acronym": "Neo-Classic", 
        "arm_group": {
            "arm_group_label": "XELOX", 
            "arm_group_type": "Experimental", 
            "description": "Clinically diagnosed stage T2-3/N+M0,orT4aN+M0 according to CT/MRI scan, and resectable"
        }, 
        "brief_summary": {
            "textblock": "1. Target population:locally advanced gastric adenocarcinoma (LAGC, cT2~3/N+M0,or\n           cT4aN+M0);no previous chemo or radio therapy.\n\n        2. Primary objective:Response rate of XELOX in the neoadjuvant setting of LAGC.\n\n           Secondary objectives:\n\n             -  The progression free survival (PFS) in the perioperative treatment of  locally\n                advanced gastric adenocarcinoma (cT3/N+M0,or  cT4aN+M0);\n\n             -  percentage of pathological response ; percentage of grade 3 or 4 adverse events as\n                safety profile of perioperative treatments;\n\n             -  D2 resection -rate after neoadjuvant chemotherapy of XELOX;\n\n             -  Overall survival;\n\n             -  QOL during the whole period of treatment.\n\n        3. Trial design:This is a multicenter, single arm, open-label, phase II study to evaluate\n           the efficacy and safety of Oxaliplatin plus capecitabine(XELOX) in the perioperative\n           treatment of  locally advanced gastric adenocarcinoma in combination with D2 resection.\n\n        4. Treatment plan:Patients will be given the perioperative chemotherapy as below once\n           recruited:Schedule of Oxaliplatin plus capecitabine (XELOX) will be as follow:\n           Capecitabine 1000 mg/m2 \uff0cbid,d 1~14 every 3 weeks(treatment for 2 weeks and rest 1\n           week)Oxaliplatin\uff1a130mg/m2\uff0c iv infusion over 2h\uff0cd1,every 3 weeks.\n\n        5. Number of subjects:50 patients.Number of centers 5 sites, which have the high volume of\n           gastric operations in China, more than 500 per year."
        }, 
        "brief_title": "Oxaliplatin Plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma", 
        "completion_date": {
            "#text": "August 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Gastric Adenocarcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Stomach Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "1. Disease specific inclusion criteria:\n\n             -  Histologically documented gastricadenocarcinoma with Lauren classification\n                Clinically diagnosed stage T2-3/N+M0,orT4aN+M0 according to CT/MRI scan, and\n                resectable\n\n             -  Measurable disease is required\n\n             -  Karnofsky  score  80%.\n\n             -  Physical condition and adequate organ function to ensure the success of abdominal\n                surgery.\n\n             -  Life expectancy \u226512 weeks.\n\n             -  Adequate hematological function: Neutrophil count \u2265 1.5 \u00d7 109/L, Platelets \u2265 100 \u00d7\n                109/L and Hemoglobin \u22658g/dL .Adequate liver function: Total bilirubin \u2264 1.5 \u00d7\n                upper limit of normal (ULN); AST (SGOT) and ALT (SGPT) < 2.5 \u00d7 ULN in the absence\n                of liver metastases, or < 5 \u00d7 ULN in case of liver metastases. ALP \u2264 2.5 \u00d7 upper\n                limit of normal (ULN); ALB \u226530g/L.\n\n           Adequate renal function: Serum creatinine \u2264 1.25 x ULN, and creatinine clearance \u2265 60\n           ml/min.\n\n             -  Female subjects should not be pregnant or breast-feeding.\n\n             -  No serious concomitant disease that will threaten the survival of patients to less\n                than 5 years.\n\n        2. General inclusion criteria:\n\n             -  Male or female. Age \u2265 18 years and \u226475 years\n\n             -  Written (signed) informed consent.\n\n             -  Able to comply with study and follow-up procedures.\n\n             -  Good compliance with the treatment plan\u3002\n\n             -  Consent to provide tissue sample\u3002"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically documented gastricadenocarcinoma with Lauren classification Clinically\n             diagnosed stage T2-3/N+M0,orT4aN+M0 according to CT/MRI scan, and resectable\n\n          -  Measurable disease is required\n\n          -  Karnofsky score 80%.\n\n          -  Physical condition and adequate organ function to ensure the success of abdominal\n             surgery.\n\n          -  Life expectancy \u226512 weeks.\n\n          -  Adequate hematological function: Neutrophil count \u2265 1.5 \u00d7 109/L, Platelets \u2265 100 \u00d7\n             109/L and Hemoglobin \u22658g/dL .Adequate liver function: Total bilirubin \u2264 1.5 \u00d7 upper\n             limit of normal (ULN); AST (SGOT) and ALT (SGPT) < 2.5 \u00d7 ULN in the absence of liver\n             metastases, or < 5 \u00d7 ULN in case of liver metastases. ALP \u2264 2.5 \u00d7 upper limit of\n             normal (ULN); ALB \u226530g/L.Adequate renal function: Serum creatinine \u2264 1.25 x ULN, and\n             creatinine clearance \u2265 60 ml/min.\n\n          -  Female subjects should not be pregnant or breast-feeding.\n\n          -  No serious concomitant disease that will threaten the survival of patients to less\n             than 5 years.\n\n          -  Male or female.\n\n          -  Age \u2265 18 years and \u226475 years\n\n          -  Written (signed) informed consent.\n\n          -  Able to comply with study and follow-up procedures.\n\n          -  Good compliance with the treatment plan.\n\n          -  Consent to provide tissue sample.\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating (in case of potentially childbearing woman, pregnancy test is\n             positive)\n\n          -  Patients of child-bearing age or the potential to father a child who refuse to use\n             adequate contraception\n\n          -  Serious concomitant disorders that would compromise the safety of the patient or\n             compromise the patient's ability to complete the study, at the discretion of the\n             investigator.\n\n          -  History of another malignancy in the last 5 years with the exception of the\n             following:\n\n        Any previous palliative, adjuvant or neoadjuvant chemotherapy and/or radiotherapy. Prior\n        treatment for locally advanced or metastatic gastric cancer. Any metastatic disease will\n        render patient ineligible according to AJCC staging manual.\n\n          -  Distant metastases (M1) including distant nodal Groups (peripancreatic, para-aortic,\n             portal, retroperitoneal, mesenteric node, by CT/MRI, or PET/CT\n\n          -  Treatment within the last 30 days with any investigational drug. Concurrent\n             administration of any other cancer therapy, including cytotoxic chemotherapy,\n             hormonal therapy, and immunotherapy.\n\n          -  Active infection that in the opinion of the investigator would compromise the\n             patient's ability to tolerate therapy.\n\n          -  Poorly controlled diabetes mellitus with fasting blood sugar > 18 mM. Second primary\n             malignancy that is clinically detectable at the time of consideration for study\n             enrollment.\n\n          -  History of significant neurological or mental disorder, including seizures or\n             dementia, which would interfere compliance and sign of consent inform. any history of\n             hypersensitivity to 5-fluorouracil or platinum and other investigational drug\n\n          -  Ileus, chronic inflammatory intestinal disease or extensive resection of the small\n             intestine and other disorders which limit drug reabsorption. This includes gastric\n             dumping syndrome, indications of accelerated passage through the small intestine,\n             indications of reabsorption disorders after intestinal surgery\n\n          -  Unstable, persistent cardiac disease despite medicinal treatment, myocardial\n             infarction within 6 months before the start of the trial\n\n          -  Organ transplant patient need immunosuppression treatment.\n\n          -  Previous surgery on primary tumour; Prior palliative surgery (open and closure,\n             passage operation)\n\n          -  Any other type of tumour (e.g. leiomyosarcoma, lymphoma) or a secondary malignancy,\n             excepting basal cell skin carcinoma or basal cell carcinoma in situ of the cervix\n             which have already been successfully treated\n\n          -  Symptomatic peripheral neuropathy NCI CTC version> 3.0 grade.\n\n          -  Patients under anticoagulant therapy with warfarin or other coumarines are excluded\n             from participation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "55", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01880632", 
            "org_study_id": "ML28733"
        }, 
        "intervention": [
            {
                "arm_group_label": "XELOX", 
                "description": "Patients will be given the perioperative chemotherapy as below once recruited:\nCapecitabine \uff1a500 mg tablets\uff08Roche\uff09 Oxaliplatin\uff1a50mg/10ml\uff08according to daily practice in each center\uff09\nSchedule of Oxaliplatin plus capecitabine (XELOX) will be as follow:\nCapecitabine 1000 mg/m2 \uff0corally taken 30 minutes after meal, bid \uff0c d 1~14 every 3 weeks(treatment for 2 weeks and rest 1 week) Oxaliplatin\uff1a130mg/m2\uff0c iv infusion over 2h\uff0cd1,every 3 weeks", 
                "intervention_name": "Capecitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "XELOX", 
                "description": "Patients will be given the perioperative chemotherapy as below once recruited:\nCapecitabine \uff1a500 mg tablets\uff08Roche\uff09 Oxaliplatin\uff1a50mg/10ml\uff08according to daily practice in each center\uff09\nSchedule of Oxaliplatin plus capecitabine (XELOX) will be as follow:\nCapecitabine 1000 mg/m2 \uff0corally taken 30 minutes after meal, bid \uff0c d 1~14 every 3 weeks(treatment for 2 weeks and rest 1 week) Oxaliplatin\uff1a130mg/m2\uff0c iv infusion over 2h\uff0cd1,every 3 weeks", 
                "intervention_name": "Oxaliplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Oxaliplatin", 
                "Capecitabine", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "XELOX", 
            "perioperative treatment", 
            "locally advanced gastric adenocarcinoma", 
            "D2 resection"
        ], 
        "lastchanged_date": "February 18, 2014", 
        "location": {
            "contact": {
                "email": "liu.tianshu@zs-hospital.sh.cn", 
                "last_name": "Tianshu Liu, doctor"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200032"
                }, 
                "name": "Zhongshan Hospital Affiliated to Fudan University"
            }, 
            "investigator": {
                "last_name": "Yiyi yu, Master", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicenter, Single Arm, Open-label Trial of Oxaliplatin Plus Capecitabine (XELOX) in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma", 
        "overall_contact": {
            "email": "liu.tianshu@zs-hospital.sh.cn", 
            "last_name": "Tianshu Liu, Doctor", 
            "phone": "+861368 1973 996"
        }, 
        "overall_official": {
            "affiliation": "Medical oncology Shanghai zhongshan hospital", 
            "last_name": "Tianshu Liu, Doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "China: Food and Drug Administration", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "the response rate evaluation will be based on tumor assessment with follow-up, including chest and upper-abdominal During preoperative treatment period, CT scan will be performed every 6 -8 weeks (2 cycles after)., brain MRI  and  bone scan (ECT)  will be performed if any suspected symptoms occur.", 
            "measure": "the response rate of XELOX in the neoadjuvant setting of LAGC", 
            "safety_issue": "No", 
            "time_frame": "6 months after the last subject participating in"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01880632"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shanghai Zhongshan Hospital", 
            "investigator_full_name": "Tianshu Liu", 
            "investigator_title": "Director of Medical oncology derpartment", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "progression by the evidence of CT/MRI scan at each evaluation at neoadjuvant period or follow-up time after surgery\uff1bDuring preoperative treatment period, CT scan will be performed every 6 -8 weeks (2 cycles after).After syrgery, CT scan will be planned every 6 months, brain MRI  and  bone scan (ECT)  will be performed if any suspected symptoms occur.", 
                "measure": "the progression free survival (PFS) in the perioperative treatment of  locally advanced gastric adenocarcinoma (cT2-3/N+M0,or  cT4aN+M0)", 
                "safety_issue": "No", 
                "time_frame": "42 months after the last subject participating in"
            }, 
            {
                "description": "After surgery\uff0cthe pathological response will be measured by the pathologist for every Operation patient.", 
                "measure": "percentage of pathological response", 
                "safety_issue": "No", 
                "time_frame": "10 months after the last subject participating in"
            }, 
            {
                "description": "Adverse events and clinical laboratory tests will be recorded by CTCAE (version 4.0) during the whole treatment period.", 
                "measure": "Percentage of grade 3 or 4 adverse events as safety profile of perioperative treatments", 
                "safety_issue": "Yes", 
                "time_frame": "1 month after the last date of treatment"
            }, 
            {
                "description": "During the OS follow-up, out-patient clinic and telephone visit will be done every 3 months for the first two years, and every 6 months after two years.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "3 years after the last subject participating in"
            }, 
            {
                "description": "These assessment will be evaluated at every evaluation.", 
                "measure": "QOL during the whole period of treatment", 
                "safety_issue": "No", 
                "time_frame": "1 years after the last date of treatment"
            }
        ], 
        "source": "Shanghai Zhongshan Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Shanghai Cancer Hospital, China", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Ruijin Hospital", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Shanghai Zhongshan Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}